...
首页> 外文期刊>Applied Drug Research, Clinical Trials and Regulatory Affairs. >A Comparative Study of Pharmaceutical Incentives to Patents in India, USA and Europe
【24h】

A Comparative Study of Pharmaceutical Incentives to Patents in India, USA and Europe

机译:制药激励措施的比较研究专利在印度,美国和欧洲

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Protection of Intellectual Property Rights is a clear incentive to innovations; yet, several countries have provided further incentives to patents in Pharmaceuticals because the full patent term of 20 years is largely exhausted, before marketing authorization.Objective: The purpose of this article is to describe the various incentives to patents in the form of financial support, data exclusivity and most importantly, extended market exclusivities and comparison of various incentives to patents in the United States of America, European Union and India.Methods: The detail of incentives is collected from various articles, latest topics, books, and newspapers.Results: These incentives create a positive environment to encourage the drug development process, strengthen economic growth and improve a balance between new Pharmaceuticals in the market and access of that medicine to the general public at a reasonable price.Conclusion: European Union and the United States of America are leading in the field of incentives to patenting in Pharmaceuticals as compared to India. Indian Patent Act, 1970, needs to be re-looked in terms of data exclusivity and patent term extensions.
机译:背景:知识产权保护权利是一个明确的激励创新;一些国家提供了进一步激励机制在药品专利,因为完整的专利期限20年很大程度上筋疲力尽,在营销授权。文章是描述各种激励措施专利的形式的金融支持,数据排他性和最重要的是,扩展市场管理局和比较各种专利在美国的动机美国、欧盟和印度。收集详细的动机不同最新文章,主题、书籍和报纸。积极的环境鼓励药物开发流程,加强经济增长和改进新型药物之间的平衡在市场和访问的药公众在一个合理的价格。欧盟和美国领域的主要动机吗专利药品相比印度。该片的排他性和专利数据词的扩展。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号